JP4397693B2 - N1−(2’−ピリジル)−1,2−アルカンジアミンスルファミン酸の合成および生物学的に活性なピペラジンの合成におけるその使用 - Google Patents
N1−(2’−ピリジル)−1,2−アルカンジアミンスルファミン酸の合成および生物学的に活性なピペラジンの合成におけるその使用 Download PDFInfo
- Publication number
- JP4397693B2 JP4397693B2 JP2003576402A JP2003576402A JP4397693B2 JP 4397693 B2 JP4397693 B2 JP 4397693B2 JP 2003576402 A JP2003576402 A JP 2003576402A JP 2003576402 A JP2003576402 A JP 2003576402A JP 4397693 B2 JP4397693 B2 JP 4397693B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- alkyl
- aroyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *[C@](CNc1ccccn1)N Chemical compound *[C@](CNc1ccccn1)N 0.000 description 1
- IUXBPLUZEPYPGY-UHFFFAOYSA-N CS(OCCN(CCOS(C)(=O)=O)c1cccc2c1OCCO2)(=O)=O Chemical compound CS(OCCN(CCOS(C)(=O)=O)c1cccc2c1OCCO2)(=O)=O IUXBPLUZEPYPGY-UHFFFAOYSA-N 0.000 description 1
- DMLRSJNZORFCBD-UHFFFAOYSA-N Nc1cccc2c1OCCO2 Chemical compound Nc1cccc2c1OCCO2 DMLRSJNZORFCBD-UHFFFAOYSA-N 0.000 description 1
- YWWMGXGZLQWZGA-UHFFFAOYSA-N OCCN(CCO)c1cccc2c1OCCO2 Chemical compound OCCN(CCO)c1cccc2c1OCCO2 YWWMGXGZLQWZGA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
N−アリールピペラジンの製造方法およびそのための中間体に関する。
式A:
で示されるピペラジンは、強力な5HT1A受容体結合剤である。米国特許第6,127,357号は、中枢神経系(CNS)障害の治療に有用なピペラジン誘導体を教示している。かかるピペラジンのエナンチオマーは、5HT1A受容体に対して異なる結合能力を示しうる。したがって、これらの有効性、選択性および代謝効果は、異なりうる。WO9703982は、かかるピペラジンのある種のエナンチオマーが、改善された5HT1A結合アフィニティーおよび生物学的利用能を示すことを教示している。したがって、効果的、操作が容易で、安価かつ安全な、光学的に好ましいピペラジンを製造する別の方法が所望されている。
WO97/37655およびCignarella et al., Farmaco Ed. Sci.; 31; 1976; 194, 196は、N1−(2’ピリジル)−1,2−プロパン−ジアミンの調製および反応を議論している。
本発明は、式IIで示されるN1−(2’−ピリジル)−1,2−アルカンジアミンスルファミン酸の製造方法であって、式Iで示される化合物をNH2R’と反応させることを含む方法である:
さらに、本発明は、式IIで示される化合物およびその光学異性体を含む。
式IIで示される化合物を水素化して、R’をHに変換し、すでにHである場合、ついで、酸を用いて加水分解して、式III:
で示される化合物を形成することができる。
本発明のさらなる態様は、N−アリールピペラジンの新規製造方法およびそのための中間体を提供することである。
本発明の別の態様は、式IIで示される化合物の新規製造方法を提供することである。
本発明の別の態様および利点は、本明細書に記載の発明の詳細な説明および請求の範囲から当業者には明らかだろう。
本発明の好ましい具体例は、N1−(2’−ピリジル)−1,2−プロパンジアミンスルファミン酸を用いるN−アリールピペラジンの新規製造方法、特に、アリールが4−シアノフェニルである式VIを有するN−アリールピペラジンの製造方法である。本発明の別の好ましい具体例は、N−アリールピペラジンの調製のための固体中間体を容易に単離するための、N1−(2’−ピリジル)−1,2−プロパンジアミンスルファミン酸の新規製造方法、およびN−アリールピペラジンの調製に有用であるその新規誘導体である。
本発明は、一工程、立体選択的および収束方法での、光学的に活性なN,N’−二置換ピペラジンの合成に有用であるだろうN1−(2’ピリジル)−1,2−プロパン−ジアミンスルファミン酸を用いる方法を提供する。光学的に活性なN,N’−二置換ピペラジンは、5−HT1A(セロトニン)受容体アンタゴニストとして活性である。
式IVで示される化合物において、Lはいずれの適当な脱離基であってもよい。当業者は、どの基が本発明の実施において適しているか容易に決定できるだろう。かかる適当な脱離基の例としては、クロロ、ブロモ、メシラート、トシラートおよびp−ブロモフェニルスルホニルオキシ基が挙げられる。
酸、塩基または溶媒の存在が、本発明の反応に必要であるる場合、当該分野で公知のいずれの酸、塩基または溶媒を用いることができる当業者は、容易に、本発明を行うにあたって用いるべき、適当な溶媒、酸および塩基を同定することができるだろう。
Rf=0.31(10:1CHCl3:CH3OH);
1H NMR(DMSO)δ9.77(bs,1H,OH)、7.15−8.0(m,13H)、6.7−6.8(m,1H)、5.81(bs,1H,NH)、4.1−4.3(m,2H)、3.4(m,2H)、1.3(d,J=4.8Hz,2H);
13CNMR(DMSO)δ155.2、146.5、137.4、136.4、129.4、129.3、129.2、129.0、128.8、128.1、127.8、127.7、127.5、127.5、126.3、116.0、114.8、62.4、57.3、53.2、50.1、14.4;
IR(KBr):νmax3432、3057、3010、2931、2836、2663、2508、2330、1599、1565、1500、1474、1433cm−1;
CHN(計算値)C63.48 H5.79 N10.57、CHN(実測値)C63.38 H5.74 N10.52;
MP=203.5〜208℃
無水アセトニトリル(1mL)中の式Xで示されるジメシラート(57mg、0.14mmol)の溶液に、アミノピリジン(20mg、0.13mmol)、炭酸カリウム(52mg、0.38mmol)および臭化リチウム(26mg、0.30mmol)を加えた。反応混合物を15時間N2下で加熱還流し、ついで、室温に冷却し、ついで、セライトのパッドで濾過する。ついで、パッドをアセトニトリルで洗浄する。合した有機層をNa2SO4で乾燥し、濾過し、減圧下で濃縮して、黄色油として52g(105%)のピペラジンXI(GC/MSにより92%面積%)を得た。
Claims (15)
- Rがメチルである、請求項1記載の方法。
- アリールが4−シアノフェニルである、請求項7記載の方法。
- 式II:
で示される化合物を式III:
a)R’がH以外である場合、式IIで示される化合物を水素化して、R’をHに変換すること;および
b)R’がHである式IIで示される化合物を酸加水分解して、式IIIで示される化合物を形成することを含む方法。 - R’が、H、ベンジルおよびベンズヒドリルからなる群から選択される、請求項14記載の化合物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36345702P | 2002-03-12 | 2002-03-12 | |
PCT/US2003/007228 WO2003078396A1 (en) | 2002-03-12 | 2003-03-10 | Preparation of n1-(2’-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005526088A JP2005526088A (ja) | 2005-09-02 |
JP4397693B2 true JP4397693B2 (ja) | 2010-01-13 |
Family
ID=28041771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003576402A Expired - Fee Related JP4397693B2 (ja) | 2002-03-12 | 2003-03-10 | N1−(2’−ピリジル)−1,2−アルカンジアミンスルファミン酸の合成および生物学的に活性なピペラジンの合成におけるその使用 |
Country Status (27)
Country | Link |
---|---|
US (1) | US6784294B2 (ja) |
EP (2) | EP1801103B1 (ja) |
JP (1) | JP4397693B2 (ja) |
KR (1) | KR20040091720A (ja) |
CN (1) | CN100341854C (ja) |
AR (1) | AR038932A1 (ja) |
AT (2) | ATE449073T1 (ja) |
AU (1) | AU2003220122A1 (ja) |
BR (1) | BR0308315A (ja) |
CA (1) | CA2477886A1 (ja) |
CY (1) | CY1106677T1 (ja) |
DE (2) | DE60330199D1 (ja) |
DK (1) | DK1483243T3 (ja) |
EC (1) | ECSP045291A (ja) |
ES (2) | ES2283762T3 (ja) |
HK (1) | HK1068618A1 (ja) |
IL (1) | IL163829A0 (ja) |
MX (1) | MXPA04008731A (ja) |
NO (1) | NO20044049L (ja) |
NZ (1) | NZ535170A (ja) |
PT (1) | PT1483243E (ja) |
RU (1) | RU2314294C2 (ja) |
SI (1) | SI1483243T1 (ja) |
TW (1) | TWI288642B (ja) |
UA (1) | UA80272C2 (ja) |
WO (1) | WO2003078396A1 (ja) |
ZA (1) | ZA200408213B (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060223824A1 (en) * | 2000-11-28 | 2006-10-05 | Wyeth | Serotonergic agents |
US7504395B2 (en) * | 2001-07-20 | 2009-03-17 | Psychogenics, Inc. | Treatment for attention-deficit hyperactivity disorder |
ATE449073T1 (de) | 2002-03-12 | 2009-12-15 | Wyeth Corp | Verfahren zur herstellung von n1-(2-pyridyl)-1,2- propandiaminsulfamidsäure und ihre verwendung zur herstellung von biologisch aktiven piperazinen |
US7361773B2 (en) * | 2002-03-12 | 2008-04-22 | Wyeth | Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines |
IL163828A0 (en) * | 2002-03-12 | 2005-12-18 | Wyeth Corp | Process for making chiral 1,4-disubstituted piperazines |
US20050215561A1 (en) * | 2004-03-19 | 2005-09-29 | Krishnendu Ghosh | Pharmaceutical dosage forms and compositions |
US20070099931A1 (en) * | 2004-03-19 | 2007-05-03 | Wyeth | Pharmaceutical dosage forms and compositions |
PA8626301A1 (es) * | 2004-03-19 | 2006-12-07 | Wyeth Wyeth | Proceso para preparar derivados de n-aril-piperazina |
JP2008531694A (ja) * | 2005-03-01 | 2008-08-14 | ワイス | 結晶性および非晶性4−シアノ−n−{(2r)−2−[4−(2,3−ジヒドロ−ベンゾ[1,4]ジオキシン−5−イル)−ピペラジン−1−イル]−プロピル}−n−ピリジン−2−イル−ベンズアミド塩酸塩 |
WO2011111831A1 (ja) | 2010-03-12 | 2011-09-15 | 日本曹達株式会社 | ピリジン環含有化合物、及びハロゲン化ピコリン誘導体及びテトラゾリルオキシム誘導体の製造方法 |
EP2602248A1 (en) | 2011-12-05 | 2013-06-12 | University Of Leicester | Novel pyrrole compounds |
GB201310126D0 (en) * | 2013-06-06 | 2013-07-24 | Univ Leicester | Novel pyrrole derivatives |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE81975T1 (de) * | 1984-12-21 | 1992-11-15 | Duphar Int Res | Arzneimittel mit psychotroper wirkung. |
JPH01125357A (ja) | 1987-11-06 | 1989-05-17 | Dainippon Pharmaceut Co Ltd | トリペプチドの誘導体 |
MX9201991A (es) * | 1991-05-02 | 1992-11-01 | Jonh Wyeth & Brother Limited | Derivados de piperazina y procedimiento para su preparacion. |
WO1994024115A1 (en) | 1993-04-16 | 1994-10-27 | Santen Pharmaceutical Co., Ltd. | Novel piperazine derivative |
DK0763024T3 (da) * | 1994-06-03 | 2002-12-02 | Wyeth John & Brother Ltd | Fremgangmåde og mellemprodukter til fremstilling af piperazinderivater |
GB9411099D0 (en) | 1994-06-03 | 1994-07-27 | Wyeth John & Brother Ltd | Piperazine derivatives |
GB9514901D0 (en) * | 1995-07-20 | 1995-09-20 | American Home Prod | Piperazine derivatives |
JP2000508319A (ja) | 1996-04-10 | 2000-07-04 | メルク エンド カンパニー インコーポレーテッド | αvβ3拮抗薬 |
ATE449073T1 (de) | 2002-03-12 | 2009-12-15 | Wyeth Corp | Verfahren zur herstellung von n1-(2-pyridyl)-1,2- propandiaminsulfamidsäure und ihre verwendung zur herstellung von biologisch aktiven piperazinen |
CA2477892C (en) * | 2002-03-12 | 2010-11-23 | Gregg Brian Feigelson | Process for synthesizing chiral n-aryl piperazines |
-
2003
- 2003-03-10 AT AT07007755T patent/ATE449073T1/de not_active IP Right Cessation
- 2003-03-10 EP EP07007755A patent/EP1801103B1/en not_active Expired - Lifetime
- 2003-03-10 EP EP03716415A patent/EP1483243B1/en not_active Expired - Lifetime
- 2003-03-10 JP JP2003576402A patent/JP4397693B2/ja not_active Expired - Fee Related
- 2003-03-10 CN CNB038058421A patent/CN100341854C/zh not_active Expired - Fee Related
- 2003-03-10 AT AT03716415T patent/ATE360002T1/de not_active IP Right Cessation
- 2003-03-10 NZ NZ535170A patent/NZ535170A/xx unknown
- 2003-03-10 BR BR0308315-2A patent/BR0308315A/pt not_active IP Right Cessation
- 2003-03-10 CA CA002477886A patent/CA2477886A1/en not_active Abandoned
- 2003-03-10 DK DK03716415T patent/DK1483243T3/da active
- 2003-03-10 IL IL16382903A patent/IL163829A0/xx unknown
- 2003-03-10 SI SI200330817T patent/SI1483243T1/sl unknown
- 2003-03-10 TW TW092105099A patent/TWI288642B/zh not_active IP Right Cessation
- 2003-03-10 PT PT03716415T patent/PT1483243E/pt unknown
- 2003-03-10 DE DE60330199T patent/DE60330199D1/de not_active Expired - Lifetime
- 2003-03-10 DE DE60313301T patent/DE60313301T2/de not_active Expired - Lifetime
- 2003-03-10 ES ES03716415T patent/ES2283762T3/es not_active Expired - Lifetime
- 2003-03-10 ES ES07007755T patent/ES2334836T3/es not_active Expired - Lifetime
- 2003-03-10 WO PCT/US2003/007228 patent/WO2003078396A1/en active IP Right Grant
- 2003-03-10 US US10/385,337 patent/US6784294B2/en not_active Expired - Fee Related
- 2003-03-10 AU AU2003220122A patent/AU2003220122A1/en not_active Abandoned
- 2003-03-10 KR KR10-2004-7014252A patent/KR20040091720A/ko active IP Right Grant
- 2003-03-10 RU RU2004130314/04A patent/RU2314294C2/ru not_active IP Right Cessation
- 2003-03-10 MX MXPA04008731A patent/MXPA04008731A/es active IP Right Grant
- 2003-03-11 AR ARP030100833A patent/AR038932A1/es unknown
- 2003-10-03 UA UA20041008214A patent/UA80272C2/uk unknown
-
2004
- 2004-09-10 EC EC2004005291A patent/ECSP045291A/es unknown
- 2004-09-24 NO NO20044049A patent/NO20044049L/no not_active Application Discontinuation
- 2004-10-11 ZA ZA200408213A patent/ZA200408213B/en unknown
-
2005
- 2005-02-02 HK HK05100856A patent/HK1068618A1/xx not_active IP Right Cessation
-
2007
- 2007-06-26 CY CY20071100843T patent/CY1106677T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI109122B (fi) | Menetelmä verisuonia supistavana aineena käyttökelpoisten [(bentsodioksaani-, bentsofuraani- tai bentsopyraani)-alkyyliamino]alkyylisubstituoitujen guanidiinien valmistamiseksi ja välituote | |
KR100359393B1 (ko) | 5-ht1a 길항제로서의 피페라진유도체 및 이의 제조방법 | |
JP4397693B2 (ja) | N1−(2’−ピリジル)−1,2−アルカンジアミンスルファミン酸の合成および生物学的に活性なピペラジンの合成におけるその使用 | |
NZ233398A (en) | Aryl- or heteroaryl-substituted piperazine derivatives and pharmaceutical compositions | |
US20050014792A1 (en) | Process for preparation of pyridine derivatives | |
JP2013537875A5 (ja) | ||
CA2477892C (en) | Process for synthesizing chiral n-aryl piperazines | |
US7361773B2 (en) | Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines | |
US20040230056A1 (en) | Process for synthesizing N-aryl piperazines with chiral N'-1-[benzoyl(2-pyridyl)amino]-2-propane substitution | |
JPH09143166A (ja) | 新規な縮合インダン誘導体及びその塩 | |
JP2012153674A (ja) | ジ(アリールアミノ)アリール化合物の製造方法及びその合成中間体 | |
US8236954B2 (en) | Processes for preparing benzimidazole thiophenes | |
US6063784A (en) | Heteroaryloxyethylamines, method of preparation, application as medicine and pharmaceutical compositions containing them | |
JP2002255915A (ja) | ミドドリンの製法 | |
US6150417A (en) | Phenoxyethylamine derivatives, method of preparation application as medicine and pharmaceutical compositions containing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060302 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20091006 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091021 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121030 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |